PRRT Indications Guidelines: Who to Treat (A Collaboration between SNMMI & NANETS)
Accredited specific links:
Physicians
Technologists, Pharmacists, and Participation
Presenters: Thomas Hope, MD and Jonathan Strosberg, MD
Learning Objectives:
- Understand where 177Lutetium-dotatate might fit within the neuroendocrine tumor treatment landscape
- Understand impact of PRRT on key endpoints including progression-free survival and health-related quality of life
- Identify potential risks of 177Lutetium-dotatate, including long-term myelotoxicity
- Discuss relative and absolute contraindications to treatment
Credit type/Info: AMA, SAM, VOICE